ClinicalTrials.gov
ClinicalTrials.gov Menu

Integrated Positron Emission Tomography - Computed Tomography (PET-CT) in Patients With Pancreatic Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00885248
Recruitment Status : Unknown
Verified April 2009 by Asan Medical Center.
Recruitment status was:  Active, not recruiting
First Posted : April 21, 2009
Last Update Posted : April 21, 2009
Sponsor:
Information provided by:
Asan Medical Center

April 20, 2009
April 21, 2009
April 21, 2009
January 2009
November 2009   (Final data collection date for primary outcome measure)
Staging of pancreatic cancer [ Time Frame: 6 months after study start ]
Same as current
No Changes Posted
Diagnosis of pancreatic cancer [ Time Frame: 6 months after study start ]
Same as current
Not Provided
Not Provided
 
Integrated Positron Emission Tomography - Computed Tomography (PET-CT) in Patients With Pancreatic Cancer
Clinical Implication of Integrated PET-CT in the Patients With Pancreatic Cancer

In suspecting pancreatic cancer, dynamic phase pancreatic CT is the most effective tool in diagnosis and staging. In addition, magnetic resolution image, endoscopic ultrasonography, endoscopic retrograde pancreatography, angiography can be performed.

After introduction of functional image, PET has been suggested in the role of diagnosis and staging of pancreatic cancer. Furthermore, recently fused images of PET and CT were available.

In this study, the researchers evaluate the role of integrated PET-CT in patients with pancreatic cancer and analysis the cost-effectiveness of the integrated PET-CT.

Compared to dynamic phase pancreatic CT, integrated PET-CT will be evaluated for sensitivity, specificity and accuracy of diagnosing and staging pancreatic cancer while the gold standard for pancratic cancer is operative specimen. If the operation can't be performed, EUS-FNA of the pancreatic mass or lymph node and additional imaging modality will be preferred to laparotomy.
Observational
Observational Model: Case-Only
Time Perspective: Prospective
Not Provided
Not Provided
Probability Sample
The suspects of pancreatic cancer to visit Asan Medical Center in South Korea
Pancreatic Cancer
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Unknown status
70
Same as current
December 2009
November 2009   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Pancreatic mass suspicious of pancreatic cancer
  • No comorbidity, expected life expectancy less than 6 months
  • Consent this study in letter

Exclusion Criteria:

  • Refuse diagnostic and staging work-up
Sexes Eligible for Study: All
18 Years to 75 Years   (Adult, Older Adult)
No
Contact information is only displayed when the study is recruiting subjects
Korea, Republic of
 
 
NCT00885248
2008-0623
Yes
Not Provided
Not Provided
Myung-Hwan Kim, Department of Internal Medicine, Asan Medical Center
Asan Medical Center
Not Provided
Not Provided
Asan Medical Center
April 2009